Ki-ras mutations in codon 12 and p53 mutations (biomarkers) and cytology in bile in patients with hepatobiliary-pancreatic carcinoma

Hepato-Gastroenterology

Volumn 52, Issue 63, 2005, Pages 713-718

  Yamaguchi, Koji ^a   Nakano, Kenji ^a   Nagai, Eishi ^a   Chijiiwa, Kazuo ^a   Kinoshita, Moritoshi ^b   Ohta, Masayuki ^c   Tanaka, Masao ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Bile; Cytology; p53 mutation; Point mutation of Ki ras in codon 12

Indexed keywords

BIOLOGICAL MARKER; MOLECULAR MARKER;

ADULT; AGED; ARTICLE; ASIAN; BILE; CANCER DIAGNOSIS; CARCINOMA; CLINICAL ARTICLE; CYTOLOGY; DIAGNOSTIC ACCURACY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HEPATOBILIARY DISEASE; HEPATOBILIARY SYSTEM CANCER; HEPATOBILIARY SYSTEM CARCINOMA; HUMAN; JAPANESE; JAUNDICE; MALE; MALIGNANT NEOPLASTIC DISEASE; ONCOGENE; ONCOGENE KI RAS; PANCREAS CARCINOMA; PANCREAS DISEASE; PERCUTANEOUS TRANSHEPATIC DRAINAGE; POINT MUTATION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BILE; BILE DUCT DISEASES; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; BILE DUCTS, INTRAHEPATIC; CODON; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, RAS; HUMANS; MALE; MIDDLE AGED; PANCREATIC DISEASES; PANCREATIC NEOPLASMS; POINT MUTATION; PROTO-ONCOGENE PROTEINS P21(RAS); REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 20644467486     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Watanabe M, Asaka M, Tanaka J, Kurosawa M, Kasai M, Miyazaki T: Point mutation of K-ras gene codon 12 in biliary tract tumors. Gastroenterology 1994; 107:1147-1153.
2. Levi S, Urbano-Ispizua A, Gill R, Thomas DM, Gilbertson J, Foster C, Marshall CJ: Multiple K-ras codon 12 mutations in cholangiocarcinoma demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 1991; 51:3497-3502.
3. Almoguera C, Shibata D, Forrester K, Martin J, Amheim N, Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53:549-554.
4. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Lacono C, Hirohashi S: Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993; 142:1534-1543.
5. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Devilee K, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B: Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342:705-708.
6. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, Ranzani GN: K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994; 54:1556-1560.
7. Takagi S, Naito E, Yamanouchi H, Ohtsuka H, Kominami R, Yamamoto M: Mutation of the p53 gene in gall-bladder cancer. Tohoku J Exp Med 1994; 172:283-289.
8. Tada M, Omata M, Kawai S, Saisho H, Ohta M, Saiki RK, Sninsky JJ: Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993; 53:2472-2474.
9. Mulcahy H, Farthing MJ: Diagnosis of pancreatico-biliary malignancy: detection of gene mutations in plasma and stool. Ann Oncol 1999; 10:114-117.
10. Yamashita K, Kuba T, Shinoda H, Takahashi E, Okayasu I: Detection of K-ras point mutations in the supernatants of peritoneal and pleural effusions for diagnosis complementary to cytologic examination. Am J Clin Pathol 1998; 109:704-711.
11. Saito S, Hata M, Fukuyama R, Sakai K, Kudoh J, Tazaki H, Shimizu N: Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. Int J Urol 1997; 4:178-185.
12. Hong SJ, Lee T, Park YS, Lee KO, Chung BH, Lee SH: A PCR-RFLP method for the detection of activated H-ras oncogene with a point mutation at codon 12 and 61. Yonsei Med J 1996; 37:371-379.
13. Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE: Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994; 54:3568-3573.
14. Takeda S, Ichii S, Nakamura Y: Detection of K-ras mutations in sputum by Mutant-Allele-Specific Amplification (MASA). Hum Mutat 1993; 2:112-117.
15. Iguchi H, Sugano K, Fukayama N, Ohkura H, Sadamoto K, Ohkoshi K, Seo Y, Tomoda H, Funakoshi A, Wakasugi H: Analysis of Ki-ras codon 12 mutations in the duodenal juice of patients with pancreatic cancer. Gastroenterology 1996; 110:221-226.
16. Lee JG, Leung JW, Cotton PB, Layfield LJ, Mannon PJ: Diagnostic utility of K-ras mutational analysis on bile obtained by endoscopic retrograde cholangiopancreatography. Gastrointest Endosc 1995; 42:317-320.
17. Ito R, Tamura K, Ashida H, Nishiwaki M, Nishioka A, Yamamoto Y, Furuyama JI, Utsunomiya J: Usefulness of K-ras gene mutation at codon 12 in bile for diagnosing biliary strictures. Int J Oncol 1998; 12:1019-1023.
18. Itoi T, Takei K, Shinohara Y, Takeda K, Nakamura K, Horibe T, Sanada A, Ohno H, Matsubayashi H, Saito T, Watanabe H: K-ras codon 12 and p53 mutations in biopsy specimens and bile from biliary tract cancers. Pathol Int 1999; 49:30-37.
19. Yamashita K, Kida Y, Shinoda H, Kida M, Okayasu I: K-ras point mutations in the supernatants of pancreatic juice and bile are reliable for diagnosis of pancreas and biliary tract carcinomas complementary to cytologic examination. Jpn J Cancer Res 1999; 90:240-248.
20. Van Laethem JL, Bourgeois V, Parma J, Delhaye M, Cochaux P, Velu T, Deviere J, Cremer M: Relative contribution of Ki-ras gene analysis and brush cytology during ERCP for the diagnosis of biliary and pancreatic diseases. Gastrointest Endosc 1998; 47:479-485.
21. Sturm PD, Rauws EA, Hruban RH, Caspers E, Ramsoekh TB, Huibregtse K, Noorduyn LA, Offerhaus GJ: Clinical value of K-ras codon 12 analysis and endobiliary brush cytology for the diagnosis of malignant extrahepatic bile duct stenosis. Clin Cancer Res 1999; 5:629-635.
22. Ajiki T, Onoyama H, Yamamoto M, Fujimori T, Maeda S, Saitoh Y: Detection of point mutations in K-ras gene at codon 12 in bile from percutaneous transhepatic choledochal drainage tubes for diagnosis of biliary strictures. Int J Pancreatol 1995; 18:215-220.
23. Abbruzzese JL, Evans DB, Raijman I, Larry L, King T, Leach SD, Frazier ML: Detection of mutated c-Ki-ras in the bile of patients with pancreatic cancer. Anticancer Res 1997; 17:795-801.
24. American Joint Committee on Cancer: AJCC Cancer Staging Manual. In: Fifth Edition, Philadelphia, New York: Lippincott-Raven Publishers, 1997; pp. 97-126.
25. Sambrook J, Maniatis T, Fritsch EF: Molecular Cloning. A Laboratory Manual. 2nd Edition. New York: Cold Spring Harbor Laboratory Press, 1989.
26. Buchman VL, Chumakov PM, Ninkina NN, Samarina PP, Georgiev GP: A variation in the structure of the protein-coding region of the human p53 gene. Gene 1988; 70:245-252.
27. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Wilson JKV, Hamilton S, Vogelstein B: p53 mutations occur in combination with 17-allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990; 50:7717-7722.
28. Lemon HM, Byrnes WW: Cancer of the biliary tract and pancreas: diagnosis from cytology of duodenal aspirations. JAMA 1949; 141:254-257.
29. Foutch PG, Kerr DM, Harlan JR, Kummet TD: A prospective, controlled analysis of endoscopic cytodiagnosis for diagnosis of malignant biliary stricture. Am J Gastroenterol 1991; 86:557-580.
30. Kurzawinski T, Deery A, Dooley J, Dick R, Hobbs K, Davidson B: A prospective controlled study comparing brush and bile exfoliative cytology for diagnosing bile duct strictures. Gut 1992; 33:1675-1677.
31. Kurzawinski T, Deery A, Davidson BR: Diagnostic value of cytology for biliary stricture. Br J Surg 1993; 80:414-421.
32. Mansfield JC, Griffin SM, Wadehra V, Matthewson K: A prospective evaluation of cytology from biliary strictures. Gut 1997; 40:671-677.
33. Iitsuka Y, Hiraoka H, Kimura A, Kodoh H, Koga S: Diagnostic significance of bile cytology in obstructive jaundice. Jpn J Surg 1984; 14:207-211.
34. Cohan RH, Illescas FF, Newman GE, Braun SD, Dunnick NR: Biliary cytodiagnosis. Bile sampling for cytology. Invest Radiol 1985; 20:177-179.
35. Harell GS, Anderson MF, Berry PF: Cytologic bile examination in the diagnosis of biliary duct neoplastic strictures. AJR 1981; 137:1123-1126.
36. Renshaw AA, Madge R, Jiroutek M, Granter SR: Bile duct brushing cytology: statistical analysis of proposed diagnostic criteria. Am J Clin Pathol 1998; 110:635-640.
37. Nakajima T, Tajima Y, Sugano I, Nagao K, Sakuma A, Koyama Y, Kondo Y: Multivariate statistical analysis of bile cytology. Acta Cytologica 1994; 38:51-55.
38. Rabinovitz M, Zajko AB, Hassanein T, Shetty B, Bron KM, Schade RR, Gavaler JS, Block G, Van Thiel DH, Dekker A: Diagnostic value of brush cytology in the diagnosis of bile duct carcinoma: a study in 65 patients with bile duct strictures. Hepatology 1990; 12:747-752.
39. Tatsuta M, Yamamura H, Yamamoto R, Morii T, Okuda S, Tamura H: Carcinoembryonic antigen in the bile in patients with pancreatic and biliary cancer. Correlation with cytology and percutaneous transhepatic cholangiography. Cancer 1982; 50:2903-2909.
40. Ryan ME, Baldauf MC: Comparison of flow cytometry for DNA content and brush cytology for detection of malignancy in pancreaticobiliary strictures. Gastrointest Endosc 1994; 40:133-139.
41. Van Laethem JL, Vertongen P, Deviere J, van Rampelbergh J, Rickaert F, Cremer M, Robberecht P: Detection of c-Ki-ras gene codon 12 mutations from pancreatic duct brushings in the diagnosis of pancreatic tumours. Gut 1995; 36:781-787.
42. Fukushima N, Suzuki M, Fukayama M: Analysis of K-ras oncogene mutation directly applied to atypical cell clusters on cytologic smear slides of bile and pancreatic juice. Pathol Int 1998; 48:33-40.
43. Hayashi N, Arakawa H, Nagase H, Yanagisawa A, Kato Y, Ohta H, Takano S, Ogawa M, Nakamura Y: Genetic diagnosis identifies occult lymph node metastases undetectable by the histopathological method. Cancer Res 1994; 54:3853-3856.
44. Hayashi N, Ito I, Yanagisawa A, Kato Y, Nakamori S, Imaoka S, Watanabe H, Ogawa M, Nakamura Y: Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 1995; 345:1257-1259.
45. Dowlatshahi K, Fang M, Snider HC, Habib FA: Lymph node metastases from breast carcinoma. Cancer 1997; 80:1188-1197.
46. Ando N, Nakao A, Nomoto S, Takeda S, Kaneko T, Kurokawa T, Nonami T, Takagi H: Detection of mutant K-ras in dissected paraaortic lymph nodes of patients with pancreatic adenocarcinoma. Pancreas 1997; 15:374-378.
47. Tamagawa E, Ueda M, Takahashi S, Sugano K, Uematsu S, Mukai M, Ogata Y, Kitajima M: Pancreatic lymph nodal and plexus miscrometastases detected by enriched polymerase chain reaction and nonradioisotopic single strand conformation polymorphism analysis: A new predictive factor for recurrent pancreatic carcinoma. Clin Cancer Res 1997; 3:2143-2149.
48. Nomoto S, Nakao A, Kasai Y, Harada A, Nonami T, Takagai H: Detection of ras gene mutations in perioperative peripheral blood with pancreatic adenocarcinoma. Jpn J Cancer Res 1996; 87:793-797.
49. Mulcahy HA, Anker P, Chen X, Lyaute J, Lederry C, stroum M, Ballinger A, Alstead EM, Farthing MJG: K-ras mutation in DNA extracted from plasma of pancreatic cancer patients. Gastroenterology 1997; 112:A620.